Key facts
- OncoVerity’s last known valuation is $63.0M (Dec 2024).
- It has raised $44.0M across 2 recorded rounds; the latest was Early Stage VC ($14.0M) in Nov 2024.
- Notable investors include Argenx, CU Healthcare Innovation Fund, RefinedScience, University of Colorado Health.
- OncoVerity has filed 2 Form Ds with the SEC since 2022, most recently Dec 2024 ($14.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for OncoVerity
Funding rounds
2 roundsAbout OncoVerity
Operator of a biotechnology firm intended to develop targeted therapies for cancer. The company uses computational tools for clinical and biological data to create drugs that specifically target cancer cells, enabling doctors with an effective and safer alternative to traditional treatments.
- Sector
- Healthcare
- HQ
- Aurora, CO, United States
- Founded
- 2022
- Website
- oncoverity.com/
- Ownership
- Privately Held (backing)
OncoVerity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoVerity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoVerity in its N-PORT filings yet. We sweep new filings monthly.